EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Still the one: Transcriptional control across leukopoiesis by SPI1/PU.1

Joseph Mackie iD, Sangwan Sim iD, Lauren Y Cominsky iD, Peter A Nigrovic iD, Neil Romberg iD

Journal of Human Immunity · 04.01.2027 · 3 (1)

DOI: 10.70962/jhi.20260152 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Human Immunity, online erschienen am 12.11.2026. Verfasst von Joseph Mackie und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunology and Allergy, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Die Arbeit nennt 175 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, NIAID NIH HHS, Jeffrey Modell Foundation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The transcription factor (TF) SPI1 (historically called PU.1) is a critical pioneer TF and regulator of hematopoiesis. It exerts exquisitely dose-dependent and stage-specific control over lymphoid, myeloid, and central nervous system–resident lineages. Structurally characterized by an intrinsically disordered N-terminal transactivation region and a highly conserved C-terminal DNA-binding E26 transformation–specific domain, SPI1 can operate alone as a monomer, via homodimerization, through epigenetic interactions, and in context-dependent transcriptional partnerships. While early animal models established its essentiality for leukopoiesis, modern human genomics has unveiled direct links between altered SPI1 function and disease. Heterozygous loss-of-function germline variants cause PU.1-mediated agammaglobulinemia, whereas somatic mutations and/or regulatory alterations can drive hematologic malignancies. Dysregulated SPI1 activity is also implicated in autoimmune diseases, including rheumatoid arthritis and systemic lupus erythematosus, and neurodegenerative disorders. This review reconciles foundational murine paradigms with emerging human translational data, highlights current therapeutic landscapes, and projects how single-cell multi-omics and advanced gene editing may shape future directions in the SPI1 biomedical field.

Autor:innen und Institutionen

  • Division of Immunology and Allergy, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
  • Immunology Graduate Group, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA, USA.
  • Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Department of Pediatrics, Perelman School of Medicine, Philadelphia, PA, USA.
  • Institute for Immunology and Immune Health, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA, USA.

ORCID-Profile: Joseph Mackie, Sangwan Sim, Lauren Y Cominsky, Peter A Nigrovic, Neil Romberg

Förderung

  • NIAMS NIH HHS
  • NIAID NIH HHS
  • Jeffrey Modell Foundation
  • NHLBI NIH HHS
  • Dr. Steven Douglas Memorial Fund
  • Sayer Family
  • National Institute of Allergy and Infectious Diseases
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases

Zitieren

APA

Mackie, J., Sim, S., Cominsky, L. Y., Nigrovic, P. A., & Romberg, N. (2027). Still the one: Transcriptional control across leukopoiesis by SPI1/PU.1. Journal of Human Immunity, 3(1). https://doi.org/10.70962/jhi.20260152

Vancouver

Mackie J, Sim S, Cominsky LY, Nigrovic PA, Romberg N. Still the one: Transcriptional control across leukopoiesis by SPI1/PU.1. Journal of Human Immunity. 2027;3(1). doi:10.70962/jhi.20260152

BibTeX
@article{Mackie2027,
  author = {Mackie, Joseph and Sim, Sangwan and Cominsky, Lauren Y and Nigrovic, Peter A and Romberg, Neil},
  title = {Still the one: Transcriptional control across leukopoiesis by SPI1/PU.1},
  journal = {Journal of Human Immunity},
  year = {2027},
  volume = {3},
  number = {1},
  doi = {10.70962/jhi.20260152}
}
Kostenlos starten →